Tags : Rigosertib

Specialised Therapeutics Signs an Exclusive License Agreement with Onconova Therapeutics

Shots: Onconova to get clinical, regulatory and sales-based milestones up to $30.4M and royalties on sales.  Specialised to receive exclusive rights to commercialize rigosertib in Australia and New Zealand The collaboration is focusing on the results of P-III INSPIRE study (NCT02562443) assessing Rigosertib IV + Best Supportive Care vs Physician’s Choice plus Best Supportive Care […]Read More

Knight Therapeutics Signs an Exclusive License Agreement with Onconova for

Shots: Onconova to receive $25.55M as clinical, regulatory and commercialization milestones and royalties on sales of Rigosertib. Knight therapeutics to receive exclusive rights to commercialize Rigosertib in Canada If approved, Rigosertib would meet the unmet medical need of the patients suffering from myelodysplastic syndromes and is currently being evaluated in P-III INSPIRE study assessing Rigosertib […]Read More